KRYSHIGH SIGNALOPERATIONAL10-K

KRYS has successfully launched its first commercial product VYJUVEK internationally, expanding from U.S.-only sales in 2023 to Europe and Japan launches in 2025.

This represents a major operational milestone for the company, transitioning from a single-market commercial entity to a global commercial operation across three major regulatory jurisdictions. The international expansion significantly broadens the addressable market for their lead product and validates their manufacturing and distribution capabilities on a global scale.

Comparing 2026-02-17 vs 2025-02-19View on EDGAR →
FINANCIAL ANALYSIS

The company's financial position strengthened meaningfully across key metrics, with revenue growing by approximately one-third year-over-year and cash position expanding to nearly $500M. Operating cash flow grew substantially, reflecting improving operational efficiency and commercial execution. The healthy balance sheet expansion, including increased inventory levels and stronger stockholders' equity, supports the company's international commercialization efforts and continued pipeline investment.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+62.7%
$123.4M$200.9M

Operating cash flow surged 62.7% — exceptional cash generation, highest quality earnings signal.

Inventory
Balance Sheet
+52.7%
$26.5M$40.5M

Inventory surged 52.7% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Cash & Equivalents
Balance Sheet
+43.9%
$344.9M$496.3M

Cash position surged 43.9% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+38.1%
$742.0M$1.0B

Current assets grew 38.1% — improving short-term liquidity or inventory/receivables build.

Revenue
P&L
+33.9%
$290.5M$389.1M

Strong top-line growth of 33.9% — accelerating demand or successful expansion into new markets.

SG&A Expense
P&L
+29.1%
$113.7M$146.7M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Stockholders Equity
Balance Sheet
+28.9%
$946.4M$1.2B

Equity base grew 28.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+26.3%
$1.1B$1.3B

Asset base grew 26.3% — expansion through organic growth, acquisitions, or capital deployment.

Accounts Receivable
Balance Sheet
+21.7%
$104.7M$127.4M

Receivables grew 21.7% — monitor days sales outstanding for collection efficiency.

LANGUAGE CHANGES
NEW — 2026-02-17
PRIOR — 2025-02-19
ADDED
(Exact name of registrant as specified in its charter) ______________________________________________________________________________________________________________________________________________________________ Delaware 82-1080209 State or other jurisdiction of incorporation or organization (I.R.S.
Our vectors are amenable to formulation for non-invasive or minimally invasive routes of administration at a healthcare professional s office or in the patient s home by a healthcare professional, caregiver, or directly by the patient themselves.
Our first commercial product, VYJUVEK , is now approved in the United States, the European Union ( EU ), and Japan for the treatment of dystrophic epidermolysis bullosa ( DEB ).
We launched VYJUVEK in the United States in 2023 and started launching VYJUVEK in Europe and Japan in 2025.
Our development pipeline includes multiple clinical stage product candidates for the treatment of rare and serious diseases, and we are investing in research and development to advance and grow this pipeline.
+7 more — sign up free →
REMOVED
(Exact name of registrant as specified in its charter) ______________________________________________________________________________________________________________________________________________________________ Delaware 82-1080209 (State or other jurisdiction of incorporation or organization) (I.R.S.
Even though we have obtained FDA approval of VYJUVEK and even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain approval for them outside of the United States, which would limit our market opportunities and adversely affect our business.
Our vectors are amenable to formulation for non-invasive or minimally invasive routes of administration at a healthcare professional s office or in the patient s home by a healthcare professional.
Our development pipeline includes multiple clinical stage programs for rare and serious diseases, and we are investing in research and development to advance and grow this pipeline.
We possess exclusive rights to develop, manufacture, and commercialize our FDA approved product and our pipeline candidates throughout the world.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →